Compare Illumina, Inc. (ILMN) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sibanye Stillwater Ltd — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Sibanye Stillwater Ltd trades at $8.58 (market cap $5.66B). The key difference: Illumina, Inc. is far larger — about 4.9× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SBSW | |
|---|---|---|
Market Cap | $27.94B | $5.66B |
Sector | Health | Basic Materials |
52-Week High | $194.33 | $21.12 |
52-Week Low | $91.00 | $7.27 |
Enterprise Value | $29.33B | $7.28B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
SBSW trades at $8.59, up 7.38% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $7.30B in 2024 despite $112.13B revenue, though 2025 projections show improved EBITDA of $21.4B. Analyst consensus is mixed with 42.9% buy ratings and a $14.25 price target, representing 66% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with deep value characteristics (P/E 4.76, P/S 0.72) but faces significant execution risks amid negative ROE and ROA. Key catalysts include management's debt reduction targets and operational improvements, while commodity price volatility remains a major headwind for the mining company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
